Posted by Hugh on December 22, 2018, at 17:22:04
In reply to Re: Promising depression drugs to watch for in 2019, posted by Lamdage22 on December 22, 2018, at 16:47:42
A phase 3 clinical trial for postpartum depression is expected to be released in January. If the trial is a success, SAGE-217 could receive FDA approval for PPD by late 2019. Sage is recruiting now for their phase 3 trial for major depressive disorder. If this trial is a success, SAGE-217 could receive FDA approval for MDD in 2020 or 2021. However, if SAGE-217 is approved for PPD in 2019, physicians would be able to prescribe it off-label for MDD, bipolar I/II disorder, and insomnia.
poster:Hugh
thread:1102565
URL: http://www.dr-bob.org/babble/20181024/msgs/1102568.html